Spots Global Cancer Trial Database for androgen deprivation therapy (adt)
Every month we try and update this database with for androgen deprivation therapy (adt) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991) | NCT04191096 | Metastatic Horm... | Pembrolizumab Enzalutamide Androgen Depriv... Placebo | 18 Years - | Merck Sharp & Dohme LLC | |
| Lucrin® Depot Efficacy and Safety Monitoring Study in Patients With Advanced Prostate Cancer and Lower Urinary Tract Symptoms (LUTS) | NCT01078545 | Advanced Prosta... Lower Urinary T... | Leuprolide acet... | 50 Years - | Abbott | |
| Rezvilutamide in Patients With Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer | NCT05753566 | Prostate Cancer Biochemical Rec... | Rezvilutamide Androgen depriv... SRT | 40 Years - | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | |
| CyberKnife® as Monotherapy or Boost SBRT for Intermediate or High Risk Localized Prostate Cancer | NCT01985828 | Prostate Adenoc... | CyberKnife Androgen Depriv... Intensity Modul... | 18 Years - | Advocate Health Care | |
| Darolutamide + Androgen Deprivation Therapy (ADT) in Chinese Men With High Risk, Nonmetastatic Prostate Cancer | NCT05171387 | Prostate Cancer | Darolutamide 60... Androgen depriv... | 18 Years - | Bayer | |
| A Study of Shorter Course Hormone Therapy and Radiation for High-risk Prostate Cancer | NCT05100472 | Prostate Cancer | Androgen depriv... Brachytherapy Hypofractionate... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension | NCT04934722 | Metastatic Horm... | Pembrolizumab Enzalutamide Androgen Depriv... Placebo | 18 Years - | Merck Sharp & Dohme LLC | |
| Immune Response Evaluation in Oligorecurrent and Oligoprogressive Prostate Cancer Patients Treated With SBRT | NCT04624828 | Oligorecurrent ... | Radiotherapy androgen depriv... immune evaluati... | 18 Years - | Istituto Clinico Humanitas | |
| Radiation and Androgen Ablation for Prostate Cancer | NCT01517451 | Adenocarcinoma ... | Radiation Thera... Androgen Depriv... | 18 Years - 100 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Assessment of Bone Loss in Men Receiving Treatment for Prostate Cancer | NCT02785627 | Prostate Cancer | Comprehensive b... | 50 Years - 80 Years | University of Sheffield | |
| Study of Zoledronic Acid for Patients With Hormone-sensitive Bone Metastases From Prostate Cancer | NCT00242567 | Prostate Cancer | Zoledronic Acid Androgen Depriv... | 18 Years - | Novartis | |
| Study of the Efficacy, Safety, and Pharmacokinetics of SM88 in Patients With Prostate Cancer | NCT02796898 | Prostate Cancer Rising Prostate... | SM88 (Cohort 1) SM88 (Cohort 2) | 18 Years - | Tyme, Inc | |
| Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension | NCT04934722 | Metastatic Horm... | Pembrolizumab Enzalutamide Androgen Depriv... Placebo | 18 Years - | Merck Sharp & Dohme LLC | |
| A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer | NCT06320067 | Prostate Cancer... | Stereotactic Ab... 177Lu-PSMA-617 Niraparib and A... Abiraterone Ace... Apalutamide Androgen Depriv... Androgen Recept... Local Radiother... Prednisolone Docetaxel | 18 Years - | University College, London | |
| Focal Prostate Ablation With Androgen Deprivation and Novel Hormonal Therapy for Intermediate Risk Prostate Cancer | NCT05790213 | Prostate Cancer | Apalutamide Ora... Androgen Depriv... Focal Therapy | 18 Years - | University of Chicago | |
| Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension | NCT04934722 | Metastatic Horm... | Pembrolizumab Enzalutamide Androgen Depriv... Placebo | 18 Years - | Merck Sharp & Dohme LLC | |
| Immune Response Evaluation in Oligorecurrent and Oligoprogressive Prostate Cancer Patients Treated With SBRT | NCT04624828 | Oligorecurrent ... | Radiotherapy androgen depriv... immune evaluati... | 18 Years - | Istituto Clinico Humanitas | |
| A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer | NCT06320067 | Prostate Cancer... | Stereotactic Ab... 177Lu-PSMA-617 Niraparib and A... Abiraterone Ace... Apalutamide Androgen Depriv... Androgen Recept... Local Radiother... Prednisolone Docetaxel | 18 Years - | University College, London | |
| Abemaciclib in Combination With Androgen Deprivation Therapy for Locally Advanced Prostate Cancer | NCT04298983 | Prostate Cancer | Abemaciclib 150... Androgen depriv... Radiation Thera... | 18 Years - | University of Alabama at Birmingham | |
| Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression | NCT04363164 | Castration Resi... | Testosterone cy... Enzalutamide Testosterone en... | 18 Years - 90 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Behavioral Exercise TRaining for Men Undergoing Androgen Depr Therapy for Prostate Ca | NCT06250751 | Prostate Cancer | Behavioral Exer... | 41 Years - 85 Years | Virginia Commonwealth University | |
| Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer | NCT04736199 | Prostatic Neopl... | Darolutamide (N... Placebo Androgen depriv... | 18 Years - | Bayer | |
| An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) | NCT04076059 | Metastatic Horm... | Enzalutamide Placebo Androgen depriv... | 18 Years - | Astellas Pharma Inc | |
| A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC | NCT02489318 | Prostate Cancer | Apalutamide Placebo Androgen Depriv... | 18 Years - | Aragon Pharmaceuticals, Inc. | |
| Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer | NCT06312670 | Metastatic Horm... Prostate Cancer Prostate Adenoc... | EPI-7386 Enzalutamide Androgen Depriv... | 19 Years - | Case Comprehensive Cancer Center | |
| RESIST-ADT (Androgen Deprivation Therapy) | NCT04485767 | Prostate Cancer Physical Functi... | Progressive Res... Flexibility and... | 60 Years - | Dana-Farber Cancer Institute | |
| A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy | NCT03641560 | Metastatic Cast... | Enzalutamide Androgen depriv... | 18 Years - | Astellas Pharma Inc | |
| Study of Zoledronic Acid for Patients With Hormone-sensitive Bone Metastases From Prostate Cancer | NCT00242567 | Prostate Cancer | Zoledronic Acid Androgen Depriv... | 18 Years - | Novartis | |
| Assessment of Bone Loss in Men Receiving Treatment for Prostate Cancer | NCT02785627 | Prostate Cancer | Comprehensive b... | 50 Years - 80 Years | University of Sheffield | |
| Focal Prostate Ablation With Androgen Deprivation and Novel Hormonal Therapy for Intermediate Risk Prostate Cancer | NCT05790213 | Prostate Cancer | Apalutamide Ora... Androgen Depriv... Focal Therapy | 18 Years - | University of Chicago | |
| Behavioral Exercise TRaining for Men Undergoing Androgen Depr Therapy for Prostate Ca | NCT06250751 | Prostate Cancer | Behavioral Exer... | 41 Years - 85 Years | Virginia Commonwealth University | |
| A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy | NCT03767244 | Prostatic Neopl... | Apalutamide Androgen Depriv... Placebo | 18 Years - | Janssen Research & Development, LLC | |
| Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer | NCT06305832 | Prostate Cancer Biochemical Rec... | Rezvilutamide Androgen depriv... SRT | 40 Years - | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | |
| Dose-Escalated Proton Radiation Therapy for High-Risk Prostate Cancer | NCT03624660 | Adenocarcinoma ... | HR-A HR-B | 18 Years - 100 Years | University of Florida | |
| Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991) | NCT04191096 | Metastatic Horm... | Pembrolizumab Enzalutamide Androgen Depriv... Placebo | 18 Years - | Merck Sharp & Dohme LLC | |
| Maintaining Bone Strength in Men With Prostate Cancer | NCT00391950 | Prostate Cancer | Zoledronic acid | 18 Years - | Novartis | |
| Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer | NCT04489745 | Prostate Cancer | SBRT Androgen depriv... | - | VA Greater Los Angeles Healthcare System | |
| Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON) | NCT04748042 | Prostate Cancer Castrate Sensit... Oligometastatic... | Abiraterone Prednisone External Beam R... Androgen Depriv... Olaparib | 18 Years - | University of Michigan Rogel Cancer Center | |
| Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer | NCT06312670 | Metastatic Horm... Prostate Cancer Prostate Adenoc... | EPI-7386 Enzalutamide Androgen Depriv... | 19 Years - | Case Comprehensive Cancer Center | |
| RESIST-ADT (Androgen Deprivation Therapy) | NCT04485767 | Prostate Cancer Physical Functi... | Progressive Res... Flexibility and... | 60 Years - | Dana-Farber Cancer Institute | |
| An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) | NCT04076059 | Metastatic Horm... | Enzalutamide Placebo Androgen depriv... | 18 Years - | Astellas Pharma Inc | |
| Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy | NCT02217566 | Prostatic Neopl... | Abiraterone ace... Prednisone Androgen depriv... | 18 Years - | Janssen Research & Development, LLC | |
| A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy | NCT03767244 | Prostatic Neopl... | Apalutamide Androgen Depriv... Placebo | 18 Years - | Janssen Research & Development, LLC | |
| A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC) | NCT01715285 | Prostate Neopla... | Abiraterone ace... Prednisone Androgen depriv... Abiraterone ace... Prednisone Plac... | 18 Years - | Janssen Research & Development, LLC | |
| Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer | NCT04743934 | Prostate Adenoc... | Flibanserin 100... Placebo Androgen depriv... | 18 Years - | University of Alabama at Birmingham | |
| MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA) | NCT06150417 | Prostate Cancer Malignant Neopl... Secondary Malig... | Androgen depriv... Androgen recept... Local Therapy: ... Metastasis dire... | 18 Years - | Case Comprehensive Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
